RxDoctor Payments Data

John Starr, MD

Internal Medicine · Fishersville, VANPI 1780841833

Payments from drug & device makers

$691in general payments, 2019–2025

Across 24 payments — averaging $28.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$179
  • Amarin Pharma, Inc.$149
  • Novo Nordisk$93
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$84
  • Johnson & Johnson$62
  • AstraZeneca$57
  • plus $67 from 4 others

What the payments were for

  • Food & beverage$691100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$691 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$262,319
Medicare patients
626
Services billed
3,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban168$161,185
OzempicSemaglutide103$138,753
JardianceEmpagliflozin108$131,357
TrulicityDulaglutide86$114,877
XareltoRivaroxaban38$51,904
JanuviaSitagliptin Phosphate37$47,438
MounjaroTirzepatide14$21,759
FarxigaDapagliflozin Propanediol13$20,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$19,877
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$15,289
Breo ElliptaFluticasone/Vilanterol28$11,329
VascepaIcosapent Ethyl12$8,137
Varenicline Tartrate33$6,861
Omeprazole503$6,324
Spiriva RespimatTiotropium Bromide13$6,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$161,185168 claims
Novo NordiskOzempic$93$138,753103 claims
Lilly USA, LLCTrulicity, Mounjaro$11$136,637100 claims
Johnson & JohnsonXarelto$62$51,90438 claims
MerckJanuvia$12$47,43837 claims
AstraZenecaFarxiga, Symbicort$57$25,95836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Fishersville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →